Related Experiment Video
Updated: Jul 7, 2026
06:35
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Improving therapeutic options for patients with giant cell arteritis
Nicolò Pipitone1, Carlo Salvarani
1Rheumatology Unit, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy.
Current Opinion in Rheumatology
|February 19, 2008
Summary
Giant cell arteritis treatment relies on glucocorticoids. Optimal dosing and steroid-sparing agents like methotrexate, azathioprine, or aspirin are key to managing this condition effectively and minimizing side effects.
Area of Science:
- Rheumatology
- Internal Medicine
- Vasculitis Research
Background:
- Giant cell arteritis (GCA) is a systemic vasculitis primarily affecting large arteries.
- Glucocorticoids are the established first-line treatment for GCA.
Purpose of the Study:
- To review optimal glucocorticoid dosing strategies for GCA.
- To identify effective glucocorticoid-sparing agents for GCA management.
Main Methods:
- Systematic review of existing literature on GCA treatment.
- Analysis of studies evaluating different glucocorticoid regimens.
- Evaluation of adjunctive therapies for GCA.
Main Results:
- Initial prednisone doses of 40-60 mg/day are typically sufficient.
- Higher doses (1 mg/kg/day) may be needed for patients at risk of ischemic complications.
- Methotrexate, azathioprine, and potentially TNF-alpha inhibitors can spare glucocorticoid use.
- Low-dose aspirin may reduce cranial ischemic events in GCA patients.
Conclusions:
- Individualized glucocorticoid dosing is crucial for balancing efficacy and adverse events in GCA.
- Steroid-sparing agents like methotrexate and azathioprine are valuable for long-term GCA management.
- Aspirin is recommended for GCA patients to prevent ischemic complications, barring contraindications.
Related Concept Videos
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...